Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Update

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 3,810,000 shares, a growth of 30.5% from the March 31st total of 2,920,000 shares. Approximately 15.6% of the shares of the company are sold short. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is currently 3.7 days.

Institutional Trading of Reviva Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Tang Capital Management LLC bought a new position in Reviva Pharmaceuticals in the 4th quarter valued at approximately $308,000. Cornerstone Select Advisors LLC acquired a new position in Reviva Pharmaceuticals in the 4th quarter valued at approximately $32,000. Ameriprise Financial Inc. bought a new position in shares of Reviva Pharmaceuticals during the fourth quarter valued at $84,000. Tower Research Capital LLC TRC grew its stake in shares of Reviva Pharmaceuticals by 848.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after purchasing an additional 23,953 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Reviva Pharmaceuticals in the fourth quarter worth $45,000. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Trading Down 2.0 %

Shares of Reviva Pharmaceuticals stock opened at $0.87 on Friday. The firm has a market capitalization of $40.79 million, a PE ratio of -0.79 and a beta of 0.05. The firm’s 50 day moving average is $0.94 and its 200 day moving average is $1.37. Reviva Pharmaceuticals has a 1 year low of $0.49 and a 1 year high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. As a group, research analysts anticipate that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on RVPH. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Roth Mkm started coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $7.00 price target on the stock. HC Wainwright cut their price objective on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Friday, January 10th. Finally, D. Boral Capital reiterated a “buy” rating and set a $8.00 price target on shares of Reviva Pharmaceuticals in a research report on Thursday, April 24th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $10.00.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.